Regenerative Medical Technology Group Inc.
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. EXECUTIVE COMPENSATION
| ITEM 11. | EXECUTIVE COMPENSATION. |
|---|
The following summary compensation table sets forth all compensation awarded to, earned by, or paid to the named executive officers paid by us during the years ended December 31, 2024, and 2023.
EXECUTIVE OFFICER COMPENSATION TABLE
| Name and Principal Position · Year · Salary ($) · Bonus ($) · Stock Awards ($) · Option Awards ($) · Non-Equity Incentive Plan Compensation ($) · Non-Qualified Deferred Compensation Earnings ($) · All Other Compensation ($) · Total ($) | ||||
|---|---|---|---|---|
| David Christensen | 2024 | 90,000 | - | 90,000 |
| President, Chief Executive Officer (Principal Executive Officer), Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer), Secretary And Director | 2023 | 90,000 | - | 90,000 |
Outstanding Equity Awards at the End of the Fiscal Year
We do not have any equity compensation plans and therefore no equity awards are outstanding as of December 31, 2024.
None of the members of the board of directors of the Company were compensated for services in such capacity.
Bonuses and Deferred Compensation
We do not have any bonus, deferred compensation or retirement plan. All decisions regarding compensation are determined by our board of directors.
Payment of Post-Termination Compensation
We do not have change-in-control agreements with our director or executive officer, and we are not obligated to pay severance or other enhanced benefits to our executive officer upon termination of her employment.
Employment Agreements
On August 18, 2021, the Company entered into a three-year Consulting Agreement with ETC (Enterprise Technology Consulting) owned by David Christensen. Consultant shall be compensated monthly based on annual rate of $90,000. Additionally, the agreement with ETC includes an issuance of 896 shares of Series DD Preferred Stock of the Company. The amount of 448 shares is issued on August 18, 2021, and the remaining 448 was issued on February 18, 2022.
As the Consulting Agreement has expired, the Company plans to continue with the compensation to ETC based on the annual rate of $90,000. We intend to sign a new consulting agreement with ETC in 2025.
Board of Directors
Our directors hold office until the next annual meeting of shareholders and until their successors have been duly elected and qualified. Our officers are elected by and serve at the discretion of the board of directors.
Securities Authorized for Issuance Under Equity Compensation Plans
As of December 31, 2024, we did not have any securities authorized for issuance under any equity compensation plans.
Compensation of Directors
No director received compensation for his services during the year ended December 31, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.